Sugi Predict

Sugi Predict / Compounds / SCHEMBL24616904

SCHEMBL24616904

SCHEMBL24616904

CNC(=O)c1cccc(C(C)n2ccc3cc(-c4conc4C)ccc3c2=O)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TAF1 P21675 1/20 0.36
▸ ROCK2 O75116 3/20 0.35
▸ ROCK1 Q13464 1/20 0.34
▸ EGFR P00533 2/20 0.34
▸ ERN1 O75460 1/20 0.33
▸ RAF1 P04049 4/20 0.33
▸ BRAF P15056 4/20 0.33
▸ BRD4 O60885 2/20 0.33
▸ DPP4 P27487 2/20 0.33
▸ MTOR P42345 1/20 0.33
▸ CECR2 Q9BXF3 1/20 0.33
▸ CDK8 P49336 1/20 0.32
▸ PLK1 P53350 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ NR3C1 P04150 1/20 0.32
▸ PGR P06401 1/20 0.32
▸ NR3C2 P08235 1/20 0.32
▸ AR P10275 1/20 0.32
▸ ESR2 Q92731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29778495 0.94 ROCK2 (0.33) TAF1ROCK2ROCK1EGFRERN1
SCHEMBL24617463 0.89 ESR1 (0.33) PLK1ESR1NR3C1PGRNR3C2
SCHEMBL24617003 0.87 GCK (0.38) TAF1ROCK2EGFRRAF1BRAF
SCHEMBL24617475 0.87 GCK (0.38) TAF1ROCK2EGFRRAF1BRAF
SCHEMBL29778636 0.83 ROCK2 (0.35) TAF1ROCK2ROCK1RAF1BRAF
SCHEMBL24616972 0.83 ROCK2 (0.35) TAF1ROCK2ROCK1RAF1BRAF
SCHEMBL29778540 0.81 TSHR (0.36) EGFRRAF1BRAFESR1NR3C1
SCHEMBL24617245 0.81 ROCK2 (0.42) ROCK2ROCK1BRD4
SCHEMBL24616950 0.81 MAP1LC3B (0.45) TAF1ROCK2ROCK1EGFRMTOR
SCHEMBL24616946 0.81 ROCK2 (0.37) TAF1ROCK2ROCK1EGFRCECR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 — — US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 — — CN claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 — — EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 — — WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 — — US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 — — CN disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 TAF1 1323/4885ROCK2 1/4885ROCK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.